Table 3.
Summary of the putative drugs against COVID-19 identified by our analysis.
| Drug | Target | Company | Current use | Clinical trials (Phase) | References (PMID) | Proposed by others (PMID) |
|---|---|---|---|---|---|---|
| Triacsin C | Long-chain-fatty-acid-CoA ligase | – | – | – |
6804425 9182714 |
32743584 |
| Celgosivir | Alpha-glucosidase | Migenix | – |
NCT01619969 (2) NCT00157534 (2) NCT00002150 (2) |
19649930 24877997 |
32510142 |
| Propylthiouracil | Thyroid peroxidase | Paladin Labs Inc | Hyperthyroidism | NCT01056419 (4) |
17948378 21005687 |
– |
| 2-bromopalmitate | Lipid metabolism | – | – | – |
32332857 23844586 |
(https://doi.org/10.1101/2020.12.20.423603) |
| Lipofermata | Fatty acid transport proteins | – | – | – | 33665270 | – |
| Tunicamycin | UDP-HexNAc: polyprenol-P HexNAc-1-P transferases | – | – | NCT01754441 (–) | 22717438 | 33091582 |
| Benzyl isothiocyanate | Expression of p21/WAF1 | – | – | – |
17469845 16386831 |
– |
| Tipifarnib | Farnesyltransferase | Johnson and Johnson | – |
NCT00093470 (3) NCT00093990 (3) |
25878363 21725056 |
– |
| Lonafarnib | Farnesyltransferase | Eiger BioPharmaceuticals, Inc | HGPS |
NCT00109538 (3) NCT00050336 (3) NCT03719313 (3) |
17667598 23897869 |
– |
Known targets, Literature references, clinical phase and previous suggestions by other authors as anti-COVID drugs are summarized in the table.